U.S. Markets closed

Genprex, Inc. (GNPX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.9600-0.0300 (-0.75%)
At close: 4:00PM EDT
Sign in to post a message.
  • F
    Fuji
    Retails who are buying into GNPX at these rates should understand the dynamics of this thesis well. This is the first genetherapy biotech with THE BEST genetherapy delivery platform for terminal oncology (distant metastasis) indications. The general approach to avoid systemic effect (unwanted toxicity related to systemic gene expression) is to deliver the gene/s locally directly into the tumor (primary/metastatic foci). Instead Reqorsa includes the Oncoprex platform that permits systemic (IV) drug delivery with genes homing to the cancer metastasis. Extremely easy and has been PROVEN SAFE in previous Ph1 mono and Erlotinib combo trials. That data is what prompted the FDA to fast-track the development process. FTD involves the flexibility of a rolling submission. They can submit portions of the BLA in pieces and get them reviewed. Review will be accelerated assuming the Ph1/2 combo trials are declared effective by the iDMC. No Ph3 will generally be needed in this terminal indication.
    Acclaim-1 (Reqorsa-Tegrisso) Ph1 combo is targeted to initiate in Q2 2021. All manufacturing have been completed. Trial recruitment was initiated a while back. All is set for the first patient to be enrolled and then initiated (doses)!!!
    The approach will be groundbreaking as TUSC2 is not the only gene that can be used!!! It will be a great platform that any oncology focussed big Pharma will like to obtain!!!
    Bullish
  • O
    Olaf
    Step by step this company will achieve their goals. Before July 1. We will see the data which will blow this stock into stratosphere.

    NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its collaborators presented positive preclinical data for the combination of TUSC2 immunogene therapy (REQORSA™) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (NSCLC).
  • N
    Naldo
    While we patiently wait for news regarding the impending Acclaim-1 and Acclaim-2 clinical trials, it is important to remember that it has already been established in the previous GNPX phase I clinical trial that REQORSA can be safely administered intravenously in lung cancer patients with highly effective delivery of its genetic payload (TUSC2) into both primary and metastatic tumours (10 – 25 fold increase in tumour tissues compared with normal tissue), demonstrating high transfection efficiency in conjunction with low adverse effects (very important).

    REF: Lu, Charles, et al. "Phase I clinical trial of systemically administered TUSC2 (FUS1)-nanoparticles mediating functional gene transfer in humans." PloS one 7.4 (2012): e34833.

    For my part, knowing this diminishes the main concerns I would otherwise be considering with regard to REQORSA as we move closer to the impending clinical trials.

    The data from the clinical trial informs us that when applied in the clinic, REQORSA is able to effectively protect its genetic payload from degradation following intravenous administration and circulation through the venous system. Also, REQORSA is able to selectively target tumours without countering problems with aggregation of blood plasma proteins (which would otherwise render it useless). REQORSA is able to effectively facilitate tumour specific uptake of the genetic payload together with escaping degradation by the endo-lysosomal system following cellular internalization. Furthermore, the genetic payload is effectively released, transcribed and translated into functionally active copy of the TUSC2 protein.

    These are all important challenges that an effective nucleic acid delivery system has to be able to overcome. No small feature to accomplish all of this in the clinic in conjunction with low adverse effects. Importantly we already know that REQORSA successfully overcomes these barriers.

    REQORSA is one of a kind, and most of the world is still ignorant about it.
  • D
    DC
    I see GNPX as a research company with great technology and limited debt. Once, there test results are published for it's upcoming trials, which is pretty much an FDA approved slam dunk at this point, I see big pharma snapping these guys up for 4-5 times the current market value. The lack of debt and the easy uptake for any pharma with mfg. capability seems obvious. Like most all small bios, GNPX got ahead of itself with it's limited sales, but at this price, it is nothing, but market dynamics and timing pushing it down. Anyone buying here will be richly rewarded in a year, or two, if they have an ounce of patience. Most don't of course.
  • D
    Davis
    Short hedges are at it borrowing shares again! https://iborrowdesk.com/report/GNPX
  • T
    ToanNg
    GNPX mentioned for its innovative approach to safely deliver payload to highly specific target.

    https://www.genengnews.com/insights/gene-therapies-receive-a-shot-in-the-arm/amp/?__twitter_impression=true
    Bullish
  • P
    P.J.
    Waiting on the clinical trials progress and status. We should hear some back by May June timeframe. It is time for me to accumulate until then. I believe the new floor will be in $7 to $8 range.
  • B
    Bobby 🎖
    While some of you novice investors may be concerned with the price fluctuations, here is something for you to consider and why I don’t stress the day to day price as I’m a long term stress free investor. A year ago the price was at $2.14, 6 months ago price was $3.62. I have averaged up several times. Sure the price has been lower than today and higher. However look at how having patience and not stressing about the day to day price over the last year has paid off for me.

    Besides look the upcoming catalyst that several people have already shared.
    Know what you own and why, do you own due diligence! Long and strong GNPX.
    Bullish
  • M
    My Precious
    Hello all, its been a while since I post in this board. I check in on the board from time to time and I see some investors concerns about the continuous down trend from its highs barely a couple of months ago. Although I share the same concerns, in my past experience with investing on other markets, is that pay no attention to short term steady declines. For people that study graphs and deltas, they understand that most of this are related to cause and effect. GNPX is not the only one in BT that is experiencing these almost daily declines. I am also invested in AXSM and CYDY, and its also getting hammered in almost daily basis.
    One of my most effective strategy is to invest based on trends and market sympathy. Right now, the market is trending towards re-opening the economy, so Biotech and stay at home stocks are getting crushed. I do have long term investments that I invest in based on beliefs and of course personal reasons and one of them is GNPX ( GNPX was introduced a friend of my wife who is in healthcare like she is).

    So for all of you who I share the same belief in this company. Pay not attention to the short term hype and the bashings. I hope that you invested at least having a vision on what your investment will accomplish. Have patience! I feel we will be rewarded long term.
    Bullish
  • K
    Krzysztof
    Bullish
  • F
    Fuji
    My personal prediction is that GNPX will trade above the $6-7 range by June 2021. Now this is based on crude evaluation of the pipeline strength and dynamics of development timelines. Market factors can obviously prove me completely wrong but what I think is the inherent value come June 2021 is $7 anchor. We shall let the market dynamics decide.
    Now this is assuming Acclaim-1 initiated in May or June 2021!! We shall see.
    Bullish
  • M
    Mathew
    @DC- Add on the fact that Reqorsa is expected based on all data we have so far to also work alongside Tegrisso for patients WITHOUT EGFR mutations and along with KEYT for patients whose tumors aren’t high Pd-1 expressers!!!
    So the patient population that these combinations could target is much wider than when these agents are alone!!
    Overall great potential for the patients and investors!!!
    Hangin there folks!!!!
    Let the traders eat other traders who panick. It’s matter of time the traders get eaten by one another. Those who do smarting DD usually survive others are in Vegas in a Casino throwing the dice and hoping for a hit. We remain patient!!
    Bullish
  • E
    E.E
    I decided to sell some crypto profits & bought another 54,000 GNPX shares today.  It is still dirt cheap at this level.  I first bought AXSM when it was $16 & GNPX will likely be 5X more massive than AXSM, per my research......I have not posting on here in months.  But, that doesn't I am leaving this board.  I found this gem when it was $0.30........ There are constant lies & distorted truths spewing by day traders & short sellers in attempt to scare novice investors into selling your cheap shares.  Take a read of these bashers profile, what research have they shared? ......  Ask yourself why they are lying & bashing Genprex or any individuals?   I am investing in GNPX since Jan 2020, when it was $0.30, as mentioned when there was no primary resident on here.    I spent countless hours doing my own research for GNPX & my other Top-Tier stocks.  I got in GNPX early & as long the catalysts are intact, I plan to accumulate GNPX until the SP hit my PT in a few years...... I do NOT have a problem selling my Low-Tier stocks when the catalysts are no longer intact.  As for GNPX, The timeline of my research of the markets was researched.... It's not this week, or the next few months.  Good luck if you are trying to time the market.   Keep shorting if you choose.  I enjoyed some of the $38B TSLA short squeeze in 2020......I held my first MSFT stock for 20 years.  I plan to hold TSLA for another 10 years.  .......There is a reason why day traders & short sellers  bashing a good stock or individuals.....  These are short-term focused, impatience individuals......Read my previous posts about 3 types of people in the market......Try to Identify the reasons why these individuals would go to great length to try to distort the truth to scare novice investors, into selling.   I am a long-term focused investor.  If you haven't read "One up on wall street" by Peter Lynch or understand visionaries CEO like Elon, or learn the Osborne's Effect, I recommend all novice investors spend your time trying to understand these long-term focused concepts.......70% of day traders lose entire their investments.  Most short sellers go bankrupt.  It's well documented.  Many articles links have been posted on here......I mentioned the approximate timeline, of my research when I think most of the (8) KNOWN massive markets would likely be realized.   NSCLC & DIA-001 are massive markets & these clinical trials take time.......There are many other intangibles (UNKNOWN) markets that indicated during the preclinical to be potentially discovered in the future.......Lastly, I have been investing in many stocks & not all my stocks are winners, especially my Low-Tiers.  I just need one (1) of my Low-Tiers to hit big.   The rest of my Low-Tiers could go to zero.  (4) of my Top-Tiers have over 1,000% returns in 2020.  Many stocks that 10X like GNPX will retrace as much as 50%.  This is when smart investors accumulate more discounted shares.  GNPX stock has a similar beginnings as TSLA did......Building a solid foundation to execute many business plans to scale up, take time.  GNPX is no different, as it is still in its 1st inning.  As long as the catalysts are intact, I plan to accumulate more GNPX discounted shares and hold until  2026 or longer. Do your own research before investing.  Never followed anyone blindly including me. GLTA.
    Bullish
  • E
    Elizabeth
    We are new investors in GNPX and find the science fascinating! We just don't understand why the stock keeps falling even though the pre-clinical trial results were excellent. It was hard to understand the verbal presentation, but the graphs and data are self-explanatory.
  • K
    Kevin
    Pretty obvious that our resident genius on this board, little d(ouche), only appears when he’s riding public transportation to work, on his 1/2 hour lunch, and again on his way home on the bus. Please, little d(ouche), please, tell me after a 41 year career in the financial field ( we know he’s lying, but go along with it🤥) that you aren’t STILL working?? Pardon us for not listening to the guy on the bus, muttering to himself about Altium, waiting for the bus driver to let him off in a place he can actually afford............Hope you had a nice ride!! 😂🤣🤡
  • T
    Tara
    @Fuel. What happened to Hold the Fort? SP is significantly higher than back in the old days. Might not be as swift as some would have liked but IMO, GNPX is well worth the wait!
  • M
    Mahi
    It is not just Genprex that is down.. Even commercial stocks with good news are down... this is due to current market manipulations... look at below article

    https://www.griproom.com/fun/why-your-stock-is-always-red#:~:text=Pre%2Dmarket%2C%20regular%20trading%20hours,demoralizing%20it%20is%20to%20investors.&text=This%20means%20if%20a%20stock,to%20buy%20or%20sell%20stocks.
    How Wall Street manipulates a stock into seemingly being down all the time.
    How Wall Street manipulates a stock into seemingly being down all the time.
    www.griproom.com
  • P
    P.J.
    Time to accumulate as much I can and practice monk's patience. Shorts are trying to make you longs to sell shares push price down to buy it cheap. Do your due diligence.
  • D
    Davis
    Short interest is at all time high! Gnpx share price is manipulated!
  • L
    Large
    Similar Thesis in the Investment Community

    Mar. 12, 2021

    With an estimated ~$530B war chest in total, large biopharma companies will continue to drive M&A activity in 2021, the analysts at Goldman Sachs predicted in a new analysis of the sector.

    Merck (MRK +0.5%), Pfizer (PFE +0.2%), Bristol-Myers Squibb (BMY -0.2%), Sanofi (SNY -0.3%), and GlaxoSmithKline (GSK -0.5%) are likely to be at the forefront of M&A activity, the analysts argue noting the losses of exclusivity hurting the valuations of potential acquirers.

    Arvinas (ARVN -1.1%), Blueprint Medicines (BPMC -0.3%), Incyte (INCY -1.3%), Seagen (SGEN -2.5%), Mirati Therapeutics (MRTX -1.4%), and Turning Point Therapeutics (TPTX -3.3%) are highlighted as attractive stocks within oncology space.